Another coronavirus vaccine clinical trial is nearing completion.

Another vaccine development company is starting Phase 3 clinical trials in the United States and Mexico. Novovax is an American company headquartered in Gaithersburg, Maryland.

New Vaccine Like the current vaccines, the Novovax vaccine will consist of two shots. Testing is being done in areas where the pandemic has high numbers of new COVID-19 cases. The company wants to demonstrate the efficacy of its product in an area that is highly contagious.

NVX-CoV2373 This vaccine is not an mRNA variant. However, it is structured based on the coronavirus spike protein to block the transmission of the virus through the spike into the human host cell. It stimulates enhanced immune responses and creates high levels of neutralizing antibodies.

Phase 1 started in Australia in May of this year. It demonstrated high immunogenicity. All subjects responded well with high concentrations of anti-spike IgC antibodies after a single dose. 100% met the vaccine target markers after the second injection.

This vaccine has demonstrated safety through the first two clinical trials with 30,000 participants. The clinical trials are testing the vaccine’s ability to prevent coronavirus from taking hold in the body as well as provide a stout defense if it does infect the person.

Novovax insisted that 25% of the participants be 65 years or older with at least 15% Black and 15% Hispanic. Phase 3 has started in the United Kingdom while other phases are concluding in South Africa, the United States, and Australia. The company plans to monitor all participants for a minimum of 24 months.

Schedule? Data collected in the first quarter of 2021 should be enough to meet regulatory requirements for safety and efficacy. The South African trials have nearly 250 medically stabilized HIV positive patients incorporated into the trial.

Phase 3 testing begins in January in Mexico and the United States at over 100 sites. Novovax is working with the FDA to expedite approval and rapid manufacturing of vaccine doses.


Johnson & Johnson is the fourth vaccine company to enter the COVID-19 vaccine market. Novovax becomes the fifth company to enter the Phase 3 clinical trials. Targeting the spike protein makes sense. Stop the virus from transmitting viral particles into the body and the disease cannot spread.

Live Longer & Enjoy Life! – Red O’Laughlin –



One Response

Leave a Reply

Your email address will not be published. Required fields are marked *